Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy-Reference-Cited by-同舟云学术

Pharmacokinetics, safety and preliminary pharmacodynamic evaluation of DARE-VVA1: a soft gelatin capsule containing tamoxifen for the treatment of vulvovaginal atrophy

Published:2023-06-08 Issue:5 Volume:26 Page:479-488
ISSN:1369-7137
Container-title:Climacteric
language:en
Short-container-title:Climacteric

Author:

Thurman A.¹,Hull L.²,Stuckey B.³,Hatheway J.¹,Mauck C.¹,Zack N.¹,Friend D.¹

Affiliation:

1. Daré Bioscience, Inc., San Diego, CA, USA

2. PARC Clinical Research and Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

3. Keogh Institute for Medical Research, Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, WA, Australia

Funder

Dare Bioscience

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13697137.2023.2211763

Reference28 articles.

1. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

2. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management

3. New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review

4. Prevalence and Impact of Vaginal Symptoms among Postmenopausal Women

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced drug delivery technologies for postmenopausal effects;Journal of Controlled Release;2024-09

2. Endocrine consequences of breast cancer therapy and survivorship;Climacteric;2024-06-12